Results 51 to 60 of about 1,634 (161)

Efectividad de la inmunización con nirsevimab en neonatos para prevenir hospitalizaciones por virus respiratorio sincitial durante dos temporadas en Navarra

open access: yesAnales del Sistema Sanitario de Navarra
Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano   +11 more
doaj   +1 more source

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania

open access: yesJournal of Paediatrics and Child Health, Volume 62, Issue 7, Page 1113-1120, July 2026.
ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt   +17 more
wiley   +1 more source

Long‐acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention

open access: yes
Pediatric Investigation, EarlyView.
Ran Wang   +3 more
wiley   +1 more source

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

open access: yesiNew Medicine, Volume 2, Issue 2, June 2026.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng   +3 more
wiley   +1 more source

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

open access: yesFrontiers in Immunology
BackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang   +15 more
doaj   +1 more source

Impact of Respiratory Viral Codetections on RSV Disease Burden in Young Children in Primary Care

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.
ABSTRACT Background Young children with respiratory syncytial virus (RSV) often have viral coinfections. This study assessed the impact of respiratory viral codetections on RSV disease burden in children < 5 years and whether this varies by specific codetected viruses.
Levi Duijst   +16 more
wiley   +1 more source

Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.
ABSTRACT After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction.
Wei Cai   +14 more
wiley   +1 more source

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

open access: yesThe Lancet Microbe
Summary: Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high ...
ProfPhD Slim Fourati   +202 more
doaj   +1 more source

Impact of the 2025 New South Wales Respiratory Syncytial Virus Prevention Program on Infant Notifications and Hospitalisations: A Population‐Based Analysis

open access: yesMedical Journal of Australia, Volume 224, Issue 6, June 2026.
ABSTRACT The 2025 NSW RSV Prevention Program, which achieved an estimated coverage of 63% maternal vaccination and 18% for infant immunisation, led to more than 40% reduction in RSV notifications and hospitalisations among infants aged younger than 6 months.
Janaki Amin   +4 more
wiley   +1 more source

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan

open access: yesInfectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease, and the standard prevention strategy in Japan is limited to high-risk infants.
Shinichi Noto   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy